News - Page 181 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article IntelGenx Announces Shareholder Approval of atai Investment

IntelGenx Announces Shareholder Approval of atai Investment

Post published:May 11, 2021
Post category:Press Release

Numinus Wellness and Optimi Health Submit All-Natural Psilocybin Extract to Health Canada for Pre-Clinical Trial Application

Post published:May 11, 2021
Post category:Press Release

Read more about the article CB Therapeutics Closes on Oversubscribed Series A

CB Therapeutics Closes on Oversubscribed Series A

Post published:May 10, 2021
Post category:Press Release

Numinus Congratulates MAPS on Phase 3 Clinical Trial Demonstrating Significant Benefits of MDMA-Assisted Therapy for Severe PTSD

Post published:May 10, 2021
Post category:Press Release

Read more about the article Wesana Health Commences Trading on the CSE

Wesana Health Commences Trading on the CSE

Post published:May 10, 2021
Post category:Press Release

Read more about the article Tryp Therapeutics Partners with Clinlogix for Clinical Trial Support

Tryp Therapeutics Partners with Clinlogix for Clinical Trial Support

Post published:May 10, 2021
Post category:Press Release

Read more about the article Psychedelic Research Bulletin: April 2021

Psychedelic Research Bulletin: April 2021

Post published:May 9, 2021
Post category:Psychedelics Research Review

Read more about the article Psychedelic Bulletin: MDMA Sees Success at Phase 3; MindMed Targets Pain; the Proliferation of Deuteration

Psychedelic Bulletin: MDMA Sees Success at Phase 3; MindMed Targets Pain; the Proliferation of Deuteration

Post published:May 8, 2021
Post category:Psychedelic Bulletin

Read more about the article Small Pharma Provides Update to Patent Portfolio Including Receipt of an in Order for Grant Notice for its Patent Related to Psychedelic Tryptamines

Small Pharma Provides Update to Patent Portfolio Including Receipt of an in Order for Grant Notice for its Patent Related to Psychedelic Tryptamines

Post published:May 7, 2021
Post category:Press Release

Read more about the article Gilgamesh Pharmaceuticals Closes On $27 Million Series A Round

Gilgamesh Pharmaceuticals Closes On $27 Million Series A Round

Post published:May 6, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.